ClinicalTrials.gg
CompletedNCT04714476Updated Feb 5, 2025

Feasibility Study Focusing on Fit of Made-to-measure Compression Garments in Healthy Subjects II

An interventional study of Made-to-measure compression garment in Product Use Issue, sponsored by BSN Medical GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by BSN Medical GmbH · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Fit of made-to-measure compression garments in healthy subjects will be tested on one day, simulating daily activities.

Read the detailed description

Lower extremities of 36 healthy subjects will be measured by trained experts to collect measures for made-to-measure compression garments.

Fit of made-to-measure compression garments, which are not on the market yet, among healthy subjects will be tested on one day, simulating daily activities. Fit will be assessed directly after donning and after a wearing period of maximum 7 hours at the study site by trained experts. Healthy subjects will give back study products at the end of the wearing period. AEs will be documented throughout the study.

02

Conditions studied

  • Product Use Issue
03

In context

Lead sponsor

BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men, women or diverse
  • Full legal competence
  • Age between 18 and 70 years
  • Capability to understand the subject information and to provide conscious
  • All female or diverse subjects of must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of with a failure rate of a Pearl-Index less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices, sexual abstinence or vasectomized partner for at least 4 weeks
  • Willingness to conduct a urine pregnancy test for all female or diverse subjects of childbearing potential
  • Capability and willingness to follow protocol requirements
  • Signed informed consent for study participation and data protection regulations
  • >23 kg/m² and ≤ 40 kg/m²

Exclusion criteria

Exclusion Criteria:

  • Circumference of the largest circumference of the upper leg >90 cm (measured in the upright position)
  • Shape distortions between the waist and the feet
  • Diagnosed lymphedema of the lower extremities
  • Diagnosed lipedema of lower extremities
  • Diagnosed indication for therapy with flat-knitted compression garments
  • Alcohol abuse as reported by subject and/ or suspected by investigator
  • Drug abuse as reported by subject and/ or suspected by investigator
  • Allergy or sensitivity to one or more components of the devices, as far as reported by the subject
  • Pregnancy or breastfeeding
  • Diagnosed peripheral arterial disease
  • Presence of untreated phlebitis, or septic phlebitis
  • Diagnosed progressed arterial insufficiency including ischemia
  • Diagnosed congestive heart failure
  • Diagnosed hypertension
  • Diagnosed renal insufficiency or kidney failure
  • Presence of Untreated or progressing skin infection
  • Presence of large coagulum in the leg vein
  • Presence of phlegmasia coerulea dolens
  • Diagnosed Raynaud's disease
  • Diagnosed gonarthrosis
  • Diagnosed ankle arthrosis
  • Diagnosed rheumatoid arthritis
  • Presence of exuding dermatoses
  • Presence of gangrene
  • Diagnosed malign lymphedema
  • Diagnosed psoriasis
  • Diagnosed diabetes mellitus
  • Diagnosed complex regional pain syndrome (CRPS; Sudeck atrophy)
  • Diagnosed polyneuropathy
  • Diagnosed severe impaired skin sensitivity und impaired sensitivity of the extremities, including all sensory malfunctions and diagnosed impaired pain sensitivity
  • Objections of the investigator to the subject's participation in the trial due to medical reasons or any other reason for which the subject should not participate in the opinion of the investigator
  • Participation in any clinical investigation with systemic and/or pharmaceutical substances within the last 4 weeks and/or in parallel
  • Sponsors, manufacturers or CRO staff
  • Surgery in the test area within the last 4 weeks
  • Open wounds in the test area
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Fit test of made-to-measure garments

    Healthy subjects will test made-to-measure compression garments

    Device: Made-to-measure compression garment

Interventions

  • DeviceMade-to-measure compression garment

    Subjects will wear one of two made-to-measure compression garments: (1) JOBST® Confidence leggins (BT) and (2) JOBST® Confidence Bermuda (ET)

06

What researchers measure

Primary outcomes

  1. Evaluation of the fit of the investigational device

    Evaluation of the fit of the investigational medical device at the end of a wearing period of approximately 4 - 7 hours, to be worn by healthy subjects once. The fit will be evaluated visually as well as manually by predefined criteria, e.g. fit of the upper hem, fit of the investigational medical device at the body area, fit at the thighs, fit in the knee area, fit at the lower hem. The fit will be evaluated using a Visual Analog Scale VAS-10 (0=very good to 10= worse).

    Time frame: One day

07

Study locations

1 site
  • proDERM GmbH Institut für Angewandte Dermatologische Forschung
    Schenefeld, Schleswig-Holstein 22869, Germany
08

References and documents

Individual participant data

Plan to share: No — No IPD will be shared. Data are needed for confidential medical device development.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Mar 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 19, 2021
StartActual
Feb 23, 2021
Primary completionActual
Mar 12, 2021
CompletionActual
Mar 12, 2021
Last update
Feb 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04714476
Lead sponsor
BSN Medical GmbH
Collaborators
proDERM GmbH
Responsible party
Sponsor
First posted
Jan 19, 2021
Start date
Feb 23, 2021
Primary completion
Mar 12, 2021
Completion
Mar 12, 2021
Last update
Feb 5, 2025

Study contacts

Kirstin Deuble-Bente, Dr.
principal investigator · proDERM GmbH Institut für Angewandte Dermatologische Forschung

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion